Integral Health Asset Management LLC Sells 375,000 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)

Integral Health Asset Management LLC reduced its stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 38.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 600,000 shares of the biopharmaceutical company's stock after selling 375,000 shares during the quarter. Integral Health Asset Management LLC owned 0.53% of Fate Therapeutics worth $990,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in FATE. JPMorgan Chase & Co. lifted its position in Fate Therapeutics by 18.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,837,304 shares of the biopharmaceutical company's stock worth $6,431,000 after buying an additional 283,080 shares in the last quarter. American Century Companies Inc. lifted its position in Fate Therapeutics by 6.6% during the 4th quarter. American Century Companies Inc. now owns 197,704 shares of the biopharmaceutical company's stock worth $326,000 after buying an additional 12,295 shares in the last quarter. SG Americas Securities LLC lifted its position in Fate Therapeutics by 30.6% during the 4th quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 10,511 shares in the last quarter. Barclays PLC lifted its position in Fate Therapeutics by 245.3% during the 3rd quarter. Barclays PLC now owns 424,277 shares of the biopharmaceutical company's stock worth $1,485,000 after buying an additional 301,389 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its position in Fate Therapeutics by 22.0% during the 4th quarter. Hsbc Holdings PLC now owns 109,422 shares of the biopharmaceutical company's stock worth $179,000 after buying an additional 19,706 shares in the last quarter. 97.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on FATE shares. Wedbush reissued a "neutral" rating and set a $5.00 price target on shares of Fate Therapeutics in a research report on Thursday, March 6th. StockNews.com raised shares of Fate Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday. Barclays lowered their price objective on shares of Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating on the stock in a research note on Wednesday. Wells Fargo & Company lowered their price objective on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 6th. Finally, Robert W. Baird lowered their price objective on shares of Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating on the stock in a research note on Wednesday. Eight equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Fate Therapeutics presently has an average rating of "Hold" and a consensus target price of $4.14.

Fate Therapeutics Trading Up 5.9%

Shares of Fate Therapeutics stock traded up $0.06 during trading on Friday, hitting $1.07. 2,096,528 shares of the stock were exchanged, compared to its average volume of 2,243,338. Fate Therapeutics, Inc. has a 1-year low of $0.66 and a 1-year high of $5.92. The stock has a market capitalization of $122.63 million, a price-to-earnings ratio of -0.65 and a beta of 2.32. The company has a fifty day moving average price of $1.01 and a 200-day moving average price of $1.51.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.07. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The business had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.18 million. Equities research analysts forecast that Fate Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.